GlassScriptPhysician profile
Priyanka Mathias
NPI 1699151522
$2,976.63
in general payments reported to CMS, 2019-2025
31 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2024: $1,106 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.38 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $339.87 | 2024-2025 | Tepezza, Repatha, Evenity |
| Corcept Therapeutics | $283.04 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.47 | 2024-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $215.68 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $164.80 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $152.66 | 2024-2025 | Freestyle Libre 3 |
| Insulet Corporation | $143.48 | 2024-2025 | Omnipod |
| Medtronic Minimed, INC. | $137.96 | 2019 | |
| Recordati_rare_diseases_inc. | $133.51 | 2024-2025 | Isturisa, Signifor Lar |
| Cequr Corporation | $120.17 | 2024-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $111.76 | 2024-2025 | |
| Beta Bionics, INC. | $94.65 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Radius Health, INC. | $94.58 | 2024-2025 | Tymlos |
| Novo Nordisk INC | $90.87 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $88.86 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $76.83 | 2025 | Twiist |
| Amneal Pharmaceuticals LLC | $70.49 | 2024-2025 | Unithroid |
| Lexicon Pharmaceuticals, INC. | $54.40 | 2024 | |
| Xeris Pharmaceuticals, INC. | $40.79 | 2025 | Recorlev, Gvoke Hypopen |
| Inspire Medical Systems, INC. | $38.70 | 2025 | Inspire |
| Neurocrine Biosciences, INC. | $33.64 | 2025 | |
| Nevro Corp. | $33.08 | 2024 | Senza |
| Abbvie INC. | $30.48 | 2025 | |
| Madrigal Pharmaceuticals | $29.82 | 2025 | Rezdiffra |
| Globus Medical, INC. | $26.05 | 2025 | Senza |
| Rgh Enterprises LLC | $25.44 | 2025 | |
| Dexcom, INC. | $24.39 | 2024 | Dexcom G6 Transmitter |
| Rhythm Pharmaceuticals, INC. | $23.91 | 2025 | Imcivree |
| Ascendis Pharma Endocrinology INC | $23.84 | 2025 | Yorvipath |
| Ascensia Diabetes Care US INC. | $19.67 | 2024 | |
| Ibsa Pharma INC. | $14.74 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priyanka Mathias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.